Showing results (231-240 of 289) with videos related to

Sort By:
Pageof 29
European Urology|October 4, 2021
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES StudyCristina Masini, Cinzia Iotti, Ugo De Giorgi, et al.
European Urology|October 10, 2022
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 TrialFrancesca Vignani, Rosa Tambaro, Ugo De Giorgi, et al.
Tumori|July 3, 2019
Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM)Maria Giuseppa Vitale, Sergio Bracarda, Laura Cosmai, et al.
Prostate Cancer and Prostatic Diseases|February 12, 2024
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer careVincenza Conteduca, Piergiorgio Di Tullio, Rossana Allamprese, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2013
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohortRoberto Iacovelli, Giacomo Cartenì, Cora N Sternberg, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2020
Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancerOrazio Caffo, Donatello Gasparro, Giuseppe Di Lorenzo, et al.
Future Oncology (London, England)|March 20, 2014
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community settingGiuseppe Procopio, Lisa Derosa, Angela Gernone, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2022
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound studyGuilhem Roubaud, Mustafa Özgüroğlu, Nicolas Penel, et al.
European Urology|March 23, 2024
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 StudyRoberto Iacovelli, Chiara Ciccarese, Sebastiano Buti, et al.
American Journal of Clinical Oncology|February 22, 2021
Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7)Daniele Santini, Marco Stellato, Ugo De Giorgi, et al.
Pageof 29